- Home
- ROIV vs MTZ Comparison
ROIV vs MTZ Comparison
Compare ROIV & MTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- MTZ
- Stock Information
- Founded
- ROIV 2014
- MTZ 1929
- Country
- ROIV United Kingdom
- MTZ United States
- Employees
- ROIV N/A
- MTZ N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- MTZ Water Sewer Pipeline Comm & Power Line Construction
- Sector
- ROIV Health Care
- MTZ Industrials
- Exchange
- ROIV Nasdaq
- MTZ Nasdaq
- Market Cap
- ROIV 8.4B
- MTZ 9.3B
- IPO Year
- ROIV N/A
- MTZ N/A
- Fundamental
- Price
- ROIV $10.38
- MTZ $115.24
- Analyst Decision
- ROIV Strong Buy
- MTZ Strong Buy
- Analyst Count
- ROIV 6
- MTZ 15
- Target Price
- ROIV $17.10
- MTZ $157.40
- AVG Volume (30 Days)
- ROIV 6.9M
- MTZ 1.4M
- Earning Date
- ROIV 02-10-2025
- MTZ 05-01-2025
- Dividend Yield
- ROIV N/A
- MTZ N/A
- EPS Growth
- ROIV N/A
- MTZ N/A
- EPS
- ROIV N/A
- MTZ 2.06
- Revenue
- ROIV $122,585,000.00
- MTZ $12,303,464,000.00
- Revenue This Year
- ROIV N/A
- MTZ $9.83
- Revenue Next Year
- ROIV N/A
- MTZ $8.84
- P/E Ratio
- ROIV N/A
- MTZ $55.94
- Revenue Growth
- ROIV 140.04
- MTZ 2.56
- 52 Week Low
- ROIV $9.96
- MTZ $82.29
- 52 Week High
- ROIV $13.06
- MTZ $166.95
- Technical
- Relative Strength Index (RSI)
- ROIV 42.16
- MTZ 40.02
- Support Level
- ROIV $10.63
- MTZ $122.81
- Resistance Level
- ROIV $11.42
- MTZ $132.49
- Average True Range (ATR)
- ROIV 0.36
- MTZ 5.41
- MACD
- ROIV -0.02
- MTZ 0.33
- Stochastic Oscillator
- ROIV 7.59
- MTZ 29.51
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About MTZ MasTec Inc.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.